Compare AU
Compare CURE vs. INCM
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Global Income Leaders ETF (INCM). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | INCM | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 13 |
Median incremental investment | $619.50 | $1,293.46 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $4,763.40 |
Average age group | > 35 | > 35 |
Key Summary
CURE | INCM | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | INCM.AX was created on 2018-10-18 by BetaShares. The fund's investment portfolio concentrates primarily on high dividend yield equity. The fund aims to track the performance of an index (before fees and expenses) that comprises 100 high-yielding global companies (ex-Australia) selected for their potential to generate attractive and sustainable income. |
Top 3 holdings | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) | ALTRIA GROUP INC (3.34 %) AT&T INC (2.08 %) VERIZON COMMUNICATIONS INC (1.92 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Other (30.45 %) Utilities (24.29 %) Consumer Staples (11.82 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (70.82 %) Korea (4.54 %) Hong Kong (3.66 %) |
Management fee | 0.45 % | 0.45 % |
Key Summary
CURE | INCM | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | Nasdaq Global Income Leaders Index - USD-US Dollar |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.45 % |
Price | $49.94 | $18.68 |
Size | $38.065 million | $36.712 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 4.13 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 22/10/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | INCM | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 13 |
Median incremental investment | $619.50 | $1,293.46 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $4,763.40 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | INCM | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | INCM |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |